

Supplemental Table 1. Urine biomarkers levels at baseline and after initiation of PrEP in iPrEx-OLE participants¹, stratified by prior TDF exposure history

Urine biomarker	Baseline			On PrEP		
	Prior TDF/FTC N=51	Placebo N=42	P-value	Prior TDF/FTC N=51	Placebo N=42	P-value
α1m (mg/dL)						
Median (IQR)	0.50 (0.50, 0.80)	0.50 (0.50, 0.80)	0.75	0.70 (0.50, 1.20)	0.70 (0.50, 1.00)	0.70
Mean ± SD	0.76±0.48	0.75±0.43		1.13±1.03	0.99±0.96	
Range	0.50, 2.30	0.50, 2.20		0.50, 5.10	0.50, 5.90	
Detectable α1m						
N (%)	19 (37.3%)	19 (45.2%)	0.44	33 (64.7%)	27 (64.3%)	0.97
Albumin/creatinine ratio (mg/g)						
Median (IQR)	4.7 (2.7, 8.8)	6.3 (3.8, 9.0)	0.32	5.2 (2.9, 9.6)	4.6 (3.2, 6.9)	0.77
Mean ± SD	7.5±8.0	8.4±10.6		8.5±11.6	7.7±11.5	
Range	0.6, 39.5	0.9, 68.1		0.6, 72.8	1.1, 69.4	
Albumin/creatinine ratio >30 mg/g						
N (%)	3 (5.9%)	1 (2.4%)	0.41	3 (5.9%)	2 (4.8%)	0.81
Protein/creatinine ratio (mg/g)						
Median (IQR)	72 (52, 103)	76 (62, 95)	0.68	88 (64, 117)	86 (73, 111)	0.83
Mean ± SD	82±40	94±106		99±58	96±47	
Range	28, 197	0, 740		15, 327	22, 320	
eGFR by CKD-EPI (ml/min/1.73m²)						
Median (IQR)	116 (104, 125)	117 (104, 123)	0.96	112 (101, 122)	109 (96, 122)	0.36
Mean ± SD	114±19	114±18		112±19	108±19	
Range	59, 161	69, 169		57, 165	68, 171	

¹Excludes 16 participants with unknown prior TDF/FTC exposure. P-values from Mann-Whitney U test and Chi-square tests for continuous and categorical variables, respectively. Abbreviations: α1m, α1-microglobulin; IQR, interquartile range; PrEP, pre-exposure prophylaxis; SD, standard deviation; TDF, tenofovir disoproxil fumarate.